Mologen AG Release: Regulatory Authority's Notification Shortens Preparation Period For dSLIM Clinical Studies
MOLOGEN AG (ISIN DE0006637200) has received a confirmation from the responsible regulatory authority, that the production of DNA based immunomodulator dSLIM does not require a manufacturing authorization according to the German pharmaceutical law (Arzneimittelgesetz). Moreover dSLIM does not fall under German gene technology law (Gentechnikgesetz).